Prosecution Insights
Last updated: November 04, 2026
Application No. 18/145,900

Indoles, Indazoles, and Related Analogs for Inhibiting YAP/TAZ-TEAD

Non-Final OA §102
Filed
Dec 23, 2022
Priority
Dec 23, 2021 — provisional 63/293,537
Examiner
SEITZ, ANTHONY JOSEPH
Art Unit
1629
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
VIB vzw
OA Round
5 (Non-Final)
68%
Grant Probability
Favorable
5-6
OA Rounds
0m
Est. Remaining
95%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allowance Rate
148 granted / 217 resolved
+8.2% vs TC avg
Strong +27% interview lift
Without
With
+26.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
59 currently pending
Career history
279
Total Applications
across all art units

Statute-Specific Performance

§101
5.1%
-34.9% vs TC avg
§103
27.6%
-12.4% vs TC avg
§102
21.9%
-18.1% vs TC avg
§112
24.2%
-15.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 217 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Status of the Claims Claims 1-4, 7-20, and 26-32 are pending and are examined on their merits. 35 U.S.C. § 112(b) Rejections Overcome by Amendment Applicant’s amendment to claim 4 in the response filed on March 17th 2025 is acknowledged. Applicant has amended the claim to further limit R4 instead of R3. As claim 4 is now further limiting to claim 1, the 112(b) rejection over claim 4 is withdrawn. Claim Objections Overcome by Amendment Applicant’s amendment to claim 1 is acknowledged. Applicant has amended claim 1 to complete the previously recited limitation for option (viii) of Z1, thus overcoming the objection for claim 1. 35 U.S.C. § 102(a)(1) Rejections Overcome by Amendment Applicant has amended the claims to no longer encompass the structures of Boes, Young, Xu, CAS RN 1519825-56-9, CAS RN 1009038-75-8, and Hinklin. All 102 rejections are thereby withdrawn. Claim Rejections - 35 USC § 102 – Necessitated by Amendment In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1, 2, 3, 4, 9, 12, and 15 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Xu (Xu et al., The Journal of Organic Chemistry 2016 81 (22), 11081-11094). Xu teaches CAS RN 2036080-77-8: PNG media_image1.png 307 372 media_image1.png Greyscale (Xu, pg. 11085, compound 4p). Xu’s compound anticipates claims 1, 2, 3, 4, 9, 12, and 15. Claims 1, 2, 8, 14, and 15 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Stambuli (US20100056800 A1). Stambuli teaches CAS RN 1213236-31-7: PNG media_image2.png 173 141 media_image2.png Greyscale (Stambuli, pg. 7). Stambuli’s compound anticipates claims 1, 2, 8, 14, and 15. Claims 1, 2, 3, 4, 7, 9, 10, 12, 13, 15, 20, 26, 27, and 31 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Song (WO 2017/120429 A1). Song teaches CAS RN 2103352-29-8: PNG media_image3.png 376 500 media_image3.png Greyscale (Song, pg. 257, 3-(N-t-butoxycarbonylaminomethyl)-1-(2-chloropyrimidin-4-yl)-1H-indole). Song’s compound anticipates claims 1, 2, 3, 4, 7, 9, 10, 12, 13, and 15. Song teaches pharmaceutical compositions of the compound (Song, pg. 519, claim 143), anticipating claim 20. Song teaches the treatment of cancers such as non-small cell lung cancer with the compound (Song, pg. 520, claim 146), anticipating claims 26 and 31. Song teaches the compound in combination with a K-Ras Inhibitor (Song, pg. 234, lines 10-15 and pg. 235 lines 8-16), anticipating claim 27. Allowable Subject Matter Claims 16-19, 28-30, and 32 are allowed. Applicant has developed the generic compound, PNG media_image4.png 160 281 media_image4.png Greyscale and particular species of the compound, which act as inhibitors for the YAP/TAZ-TEAD transcription process. The compounds of claim 19 are not found in the art. The generic compound of claim 18 includes features which distinguish it from the art. While the core structure, PNG media_image5.png 160 281 media_image5.png Greyscale , is not novel, the requirement that R9 is a pyrazole and that R10 is a C=O substituted carbon chain distinguishes the generic compound from the art. The closest structures of the art appear in Ince (WO 2012/007345 published on January 19th 2012). Ex: PNG media_image6.png 112 178 media_image6.png Greyscale (Ince, pg. 198, specification, compound 2-71). The instant generic structure shares the core structure with Ince, as well as the attached pyrazole. However, Ince requires an attached phenyl group at position R10, in contrast to the substituted carbon chain of the instant structure. As compounds of the generic structure of claim 18 are not found in the art and it is unclear how the differences between the structure and compounds known in the art would contribute to the activity of the compounds, the compounds of claims 18 and 19 are novel. Applicant has further developed particular species of the generic invention, PNG media_image7.png 149 169 media_image7.png Greyscale , a series of indole, indazole, and related compounds that act as inhibitors for the YAP/TAZ-TEAD transcription process. The particular compounds defined by applicant are not found in the art. Zbieg (U.S. Provisional Patent No. 63/283,138 published on November 24th 2021) claims TAZ-TEAD inhibitors containing similar structures to the instant claims. Ex: PNG media_image8.png 107 200 media_image8.png Greyscale PNG media_image9.png 140 134 media_image9.png Greyscale (Zbieg, claim 18 [left], instant compound 4, also found in claim 17 [right]). However, while Zbieg’s structures are similar to the species exemplified in claims 16, 17, and 28, they are not identical, and it is unclear how the differences between Zbieg’s structures and the instant structures would contribute to the activity of the compounds. For these reasons, the compounds of claims 16, 17, and 28 are novel. Consequently, claims 16-19, 28-30, and 32 are allowed. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anthony Seitz whose telephone number is (703)756-4657. The examiner can normally be reached 7:30 AM ET - 5:00 PM ET M-F. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Lundgren can be reached at (571)272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /A.J.S./Examiner, Art Unit 1629 /JEFFREY S LUNDGREN/Supervisory Patent Examiner, Art Unit 1629
Read full office action

Prosecution Timeline

Show 6 earlier events
Mar 18, 2025
Response after Non-Final Action
Jul 25, 2025
Non-Final Rejection mailed — §102
Nov 18, 2025
Response Filed
Mar 09, 2026
Final Rejection mailed — §102
Apr 01, 2026
Response after Non-Final Action
Apr 21, 2026
Request for Continued Examination
Apr 24, 2026
Response after Non-Final Action
Nov 03, 2026
Non-Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12758536
COMBINATION OF A SK2 INHIBITOR AND AN INHIBITOR OF A CHECKPOINT PATHWAY, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF
5y 3m to grant Granted Oct 13, 2026
Patent 12759985
COMPOUNDS HAVING 5-(2-FLUORO-6-HYDROXYPHENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE AS INHIBITORS OF PROTEIN KINASE PHOSPHATASE ENZYMES
2y 10m to grant Granted Oct 13, 2026
Patent 12760035
COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF
3y 1m to grant Granted Oct 13, 2026
Patent 12760020
SOLID STATE FORMS OF VERICIGUAT AND PROCESS FOR PREPARATION THEREOF
2y 8m to grant Granted Oct 13, 2026
Patent 12751938
THERAPEUTIC USES OF INHIBITORS OF THE RNA-BINDING PROTEIN HuR
4y 0m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
68%
Grant Probability
95%
With Interview (+26.9%)
3y 5m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 217 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month